• Donate
  • Contact

2017-05-25 MN Biosimilar

back to news

Minnesota Enacts HF712

Posted: May 25, 2017


Minnesota has joined the now 33 states that have enacted legislation to provide access and proper regulation to the use of biosimilar medications, as HF712 received approval from the Governor. HF712 provides that within 5 business days of dispensing a biological product to a patient, the pharmacist must communicate the specific product and manufacturer to the prescribing physician.

Minnesota joins Nevada in making final action on biosimilar legislation this week, while Maryland's bill awaits action from its Governor.

For more information on all types of patient advocacy, continue to track the CSRO website and also visit our Facebook page.

We use cookies so that we can remember you and understand how you use our site. If you do not agree with our use of cookies, please change the current settings found in our Cookie Policy. Otherwise, you agree to the use of the cookies as they are currently set. To learn more, please visit our Privacy Policy.